Summit Therapeutics Inc. Stock

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate 03:26:25 2026-10-19 pm EDT 5-day change 1st Jan Change
15.66 USD +7.07% Intraday chart for Summit Therapeutics Inc. -8.73% -10.61%

Valuation: Summit Therapeutics Inc.

Market Cap 8.77B 11.68B 10.41B 9.65B 16.46B 1,108B 16.73B 116B 45.49B 579B 43.83B 42.91B 1,850B P/E 2026 *
-12.7x
P/E 2027 * -12.5x
Enterprise Value 8.51B 11.33B 10.1B 9.36B 15.97B 1,074B 16.23B 112B 44.14B 562B 42.52B 41.63B 1,795B EV / Sales 2026 *
2,895x
EV / Sales 2027 * 209x
Free-Float
19.13%
Yield 2026 *
-
Yield 2027 * -
Sep. 22 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
Sep. 15 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
Sep. 14 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
Sep. 09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
Sep. 09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
Aug. 26 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
Aug. 26 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
Aug. 26 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
Aug. 26 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
Aug. 25 Wall Street Wants Receipts Zonebourse
Aug. 25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
Aug. 12 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
Aug. 12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day+6.73%
1 week-9.14%
Current month-7.95%
1 month-7.90%
3 months+15.30%
6 months-38.04%
Current year-11.01%
1 week 14.56
Extreme 14.56
16.79
1 month 14.56
Extreme 14.56
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 2022-07-24
Chief Executive Officer 81 2020-03-31
Director of Finance/CFO 48 2024-04-01
Director TitleAgeSince
Chairman 81 2020-01-31
Director/Board Member 48 2019-11-30
Director/Board Member 55 2020-11-10
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Free

Controller/Auditor

100,000 0.0125%
6/4/26 Buy

Chief Executive Officer

100,000 0.0129%
6/4/26 Buy

Chief Executive Officer

100,000 0.0129%
Change 5-day change 1-year change 3-year change Capi.($)
+6.73%-9.14%-22.31%+745.92% 11.7B
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+6.83%+10.89%+79.30% 51.2B
+0.30%-0.46%-0.03%+61.89% 51.19B
-0.86%+0.77%+24.61%+41.49% 43.93B
+0.69%+6.07%+16.66%+134.23% 41.96B
+2.26%-6.23%+236.73%+527.14% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+2.21%+27.96%+28.00% 22.5B
Average +1.47%-1.55%+40.22%+174.69% 38.41B
Weighted average by Cap. +1.08%-0.47%+43.37%+131.64%

Financials

2026 *2027 *
Net sales 2.94M 3.91M 3.49M 3.23M 5.52M 371M 5.61M 38.77M 15.25M 194M 14.69M 14.38M 620M 41.98M 55.92M 49.85M 46.17M 78.78M 5.3B 80.07M 554M 218M 2.77B 210M 205M 8.86B
Net income -701M -934M -832M -771M -1.32B -88.52B -1.34B -9.25B -3.64B -46.26B -3.5B -3.43B -148B -743M -990M -882M -817M -1.39B -93.82B -1.42B -9.8B -3.85B -49.04B -3.71B -3.64B -157B
Net Debt -262M -349M -311M -288M -492M -33.08B -500M -3.46B -1.36B -17.29B -1.31B -1.28B -55.27B -1.6M -2.13M -1.9M -1.76M -3M -202M -3.05M -21.09M -8.29M -106M -7.99M -7.82M -337M
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
26-10-19 $15.65 +6.94% 3,901,273
26-10-16 $14.63 -4.81% 4,331,009
26-10-15 $15.37 +1.59% 4,733,233
26-10-14 $15.13 -2.51% 4,661,710
26-10-13 $15.52 -9.40% 7,131,981
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
10.97GBP
Average target price
22.65GBP
Spread / Average Target
+106.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock